Rapley, EA ∙ Crockford, GP ∙ Teare, D ∙ et al.

There was low to moderate certainty in quality of evidence by GRADE framework. Chemotherapy, radiation, and their combination are associated with an increased risk of non-germ cell SMNs after the ...

Emactuzumab demonstrated a 71% objective response rate, rapid tumor reduction, and manageable side effects in early trials. Emactuzumab has received fast track designation from the U.S. FDA for ...

This review will focus on recent advances in our understanding of how these cells contribute to the tumor response to hypoxia in non-small-cell lung cancer. Lung cancer is the commonest cancer ...

The authors developed a novel tool, SCellBOW, to perform cell clustering and infer survival risks on individual cancer cell clusters from the single cell RNA seq dataset. The key ideas/techniques used ...

Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...

Romvimza is a medicine called a kinase inhibitor that is used to treat tenosynovial giant cell tumor (TGCT) that may be made worse by surgery. TGCT is a condition where tumors form in joints of ...

Tumor cells transform fibroblasts into cancer-associated fibroblasts, which have an important immunosuppressive activity on which growth, invasion, and metastasis depend. These activated fibroblasts ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

Background: T-cell receptor (TCR) repertoires provide insights into tumor immunology, yet their variations across digestive system cancers are not well understood. Characterizing TCR differences ...